Abstract
The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology*
-
Acetamides / therapeutic use
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Drug Resistance, Microbial
-
Humans
-
Linezolid
-
Male
-
Methicillin Resistance
-
Oxazolidinones / pharmacology*
-
Oxazolidinones / therapeutic use
-
Peritonitis / drug therapy
-
Peritonitis / microbiology
-
Protein Synthesis Inhibitors / pharmacology*
-
Protein Synthesis Inhibitors / therapeutic use
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology*
-
Staphylococcus aureus / drug effects*
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
Protein Synthesis Inhibitors
-
Linezolid